Sr. Administrative Assistant / Executive Assistant

<p><strong>About Avalyn</strong></p> <p>Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit&nbsp;<a class="web" href="https://www.globenewswire.com/Tracker?data=CUTV0SsG-Ei_lqUFR1s2Q9IFeC3BztUf2Q9VzwR--g1bp8pG5_5zAveC1plWtXdlqm_iFd4sbp6T0rZk0HdLmArRmLnA9Y8ktgQ5-MSe9AFNL9HulxYyNLq4bHe1mfDxPm2y90XOzJ0iACoQdCGleje6soZiUuCwhDxEr1VQjgRBBrAq4bFXbJkrVhzJS8_gsjTotqKyQVCpjI_pauDMWihPoxh5z2UVZouuiXVs57i60x3w3SzyJLuV-GY9ZxHuNa0gOfZTiqF9PzxJfOsr5Q==" target="_blank"><u>avalynpharma.com</u></a>&nbsp;and follow the company on&nbsp;<a class="web" href="https://www.globenewswire.com/Tracker?data=4P2X2kH6BMyR2KxZfJ2MXh0ZUOoR38a69EFti2TlA36ngqdKMtKF5-j7OecQdK76POEQqSdtzWNigv6bkSNFFmJiZ8MtoBbfONRa-pWIolzXPs1ltjLnHeGe0vyolYgNAjU3gfPV_Hvl7H58OI5Exbmk3Wq7-Qs97BgII9k3MaiTYe2qPC6xF3bKgvcyi-TqVSXu-iAmomfd39bWJqo41t97hHXQS5gOD2_vu21HwDa0EUVDPTfazlgoOdioGTpbEU6fDieVck9cnoROpPmFQw==" target="_blank"><u>LinkedIn</u></a>.</p> <p><strong><span data-contrast="auto"><span data-ccp-parastyle="No Spacing">Position Overview</span></span></strong><span data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}">&nbsp;</span></p> <p><span data-contrast="auto"><span data-ccp-parastyle="No Spacing">Avalyn is&nbsp;</span><span data-ccp-parastyle="No Spacing">seeking<